The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers

  • Lowest Price Guaranteed From USD 4,499

  • Published
    October 2019

  • Pages
    375

  • View Count
    4800

Example Insights

Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030-Context Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030-Types of cancers Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030-Treatment of different type of cancers
Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030-Benchmarking Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030-Funding & Investments Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030-Partnerships & Collaborations
Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030-Futuer Opportunity Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030-Market Forecast  

 

Overview

Cancer is known to be one of the leading causes of death worldwide. In 2019, 0.6 million deaths due to cancer are estimated in the US alone. Moreover, the World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years.  One of the primary reasons for the high mortality associated with this condition is believed to be late diagnosis. This results in delayed treatment, which severely compromises chances of survival. For many years, tissue biopsy has been considered the gold standard for cancer diagnosis. However, owing to the invasive nature of the test, biopsies cannot be repeated frequently to assess / measure disease progression or monitor therapeutic outcome. In fact, in some cases, it is not possible to carry out a biopsy because the affected tissue / organ is not amenable to undergo such a painful and traumatic procedure. This has resulted in a significant unmet need for safer and more patient friendly cancer diagnostics that are capable of offering accurate test results. 

Advances in the field of biotechnology have enabled the establishment of several minimally invasive / non-invasive approaches for disease diagnosis. Amongst other promising diagnostic tools, liquid biopsy has emerged as a versatile and promising non-invasive cancer diagnostic tool. This procedure is based on the analysis of biofluids (such as blood, urine and / or plasma) in order to detect rare forms of biomarkers / tumor markers, such as circulating tumor cells (CTCs), circulating tumor DNA / RNA (ctNAs), circulating free DNA (cfDNA) and exosomes. Moreover, liquid biopsies have been demonstrated to be capable of assessing the stage of tumor at the time of sample extraction. Additionally, owing to the non-invasive nature of the test, it can be actively used to monitor / track changes in tumors, both before and during the course of treatment. Other than liquid biopsy, the cancer diagnostics market has witnessed the emergence of several other non-invasive diagnostic technologies, which are based on analytes that are either superficially located (such as skin lesions) and / or are expelled from the body (such as bronchial fluids and exhaled breath). Most of the non-invasive diagnostic techniques mentioned above are backed by clinical data, validating their relevance and applicability across several types of solid tumors (such as breast cancer, lung cancer, ovarian cancer and pancreatic cancer) and hematological malignancies (such as leukemia and lymphoma). In future, non-invasive cancer diagnosis methods, particularly liquid biopsies, are anticipated to replace the existing invasive diagnostic techniques. 

Scope of the Report

The 'Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers' report provides an extensive study on liquid biopsy kits / assays that are either commercialized or are under development for diagnosis and / or monitoring of different types of cancer. In addition, it features an elaborate discussion on the likely future opportunity associated with such tests, over the next 10 years. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the non-invasive cancer diagnostics market, featuring information on the developers of such products and analyses based on a number of relevant parameters, such as year of establishment, company size, geographical location, current development status of proprietary liquid biopsy test (under development, research use only, and available), type of product (assay kit, software / algorithm and device), type of tumor marker analyzed (CTCs, ctDNA, cfDNA, exosomes, and others), key applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), type of analyte used (blood, urine and others) and target cancer indications.
  • An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019, based on various parameters, such as type of partnership, year of partnership, type of tumor marker, target cancer indications and the most active players.
  • An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics, including details of seed financing, venture capital financing, debt financing, grants, and capital raised via IPOs and subsequent public offerings.
  • An analysis of the initiatives of big pharma players , highlighting the key focus areas of such companies and analysis based on various relevant parameters, such as stage of development of their proprietary non-invasive cancer diagnostic test(s), key applications, type of tumor marker and target disease indications.
  • A detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2016, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • Elaborate profiles of the key players engaged in this domain, featuring a brief overview of the company, its financial information (if available), a detailed description of its product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for non-invasive cancer diagnostics. Based on various parameters, such as number of available / under development products and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others), [B] key applications (early diagnosis, patient monitoring and recurrence monitoring), [C] target disease indications (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, gastric cancer, pancreatic cancer, ovarian cancer, and others), [D] end users (hospitals, research institutes and others), and [E] key geographical regions (the US, the UK, Germany, Italy, Spain, France, Japan, Australia, China, India, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Shibichakravarthy Kannan, Founder and CEO, Theranosis Life Sciences
  • Abizar Lakdawalla, Founder, ProXeom
  • Philippe Nore, CEO and Co-founder, MiNDERA Corporation
  • Frank Szczepanski, President and CEO, IVDiagnostics
  • Mark Li, CEO, Resolution Bioscience
  • Brad Walsh, CEO, Minomic International
  • Joachim Fluhrer, Founder and Medical Director, Genostics
  • Anton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations
  • Catalina Vasquez, Chief Operating Officer, Nanostics
  • Burkhard Jansen, Chief Medical Officer, DermTech
  • Christer Ericsson, Chief Scientific Officer, iCellate Medical
  • Jake Micallef, Chief Scientific Officer, VolitionRx
  • Nathalie Bernard, Marketing Director, OncoDNA
  • Riccardo Razzini, Sales and Marketing Manager, LCM Genect
  • Peter French, Strategic Technology Advisor, Sienna Cancer Diagnostics

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the liquid biopsy market and describes its evolution in the short-mid term and long term.

Chapter 3 provides an overview of cancer statistics and the global burden of the disease. In this section of the report, we have also highlighted the importance of early detection of the disease through diagnosis and asymptomatic screening. The chapter outlines the conventional invasive diagnostic tests, which are widely used for cancer diagnosis and prognosis.

Chapter 4 discusses, in detail, the need for non-invasive cancer diagnostics and their importance. The chapter presents the underlying concept of different imaging techniques, screening assays and advanced approaches used for diagnosis of cancer, highlighting the advantages and disadvantages of each of the aforementioned techniques. 

Chapter 5 provides information on nearly 300 liquid biopsy tests that are either available or under development for multiple applications. It features a comprehensive list of product developers and analyses based on a number of parameters, such as year of establishment, company size, geographical location, current development status of various products (under development, research use only, and available), type of product (assay kits, software / algorithm, and device), type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others), applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), and target cancer indications.

Chapter 6 includes elaborate profiles of key players, featuring a brief overview of the company, its financial information (if available), a detailed description of its product portfolio, and an informed future outlook.

Chapter 7 features an in-depth analysis and discussion on the various collaborations and partnerships from 2016-2019 (till September), based on various parameters, such as, year of partnership, target cancer indications, type of type of tumor marker, and type of partnership model (namely mergers and acquisitions, licensing agreements, product development agreements, product development and commercialization agreements, research and development agreements, distribution and supply agreements, service agreements, clinical trial agreements and other agreements). It also includes a schematic representation that showcases the companies that have established the maximum number of alliances, highlighting most popular tumor markers and target disease indications. 

Chapter 8 presents details on various investments received by the start-ups / small-sized and mid-sized companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till September 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 9 features an analysis on the big pharma companies, highlighting the key focus areas of these players across various parameters, such as current stage of development, type of tumor marker, target cancer indications and key applications areas.

Chapter 10 includes a detailed acquisition target analysis, which takes into consideration the historical trend of activity of top acquirers, providing a means for industry stakeholders to identify potential acquisition targets across different geographies.

Chapter 11 provides an overview of the other non-invasive diagnostics for oncological disorders. It presents information on different diagnostics tests, including non-blood based biomarker detection tests (saliva-based biomarker detection, stool-based metabolic biomarker detection, skin-based biomarker detection, semen-based biomarker detection and urine based biomarker detection), DNA methylation detection test, fecal occult blood test and fecal immunochemical test, microRNA (miRNA) based test, pigmented lesion assay, stool DNA (sDNA) testing, and Volatile Organic Compound (VOC) detection test. The diagnostic procedures discussed in this chapter are backed up by several examples. 

Chapter 12 presents an insightful market forecast analysis, highlighting the future potential of non-invasive cancer diagnostics, till the year 2030. We have segregated the opportunity of non-invasive cancer diagnostics on the basis of the type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others), applications (early diagnosis, patient monitoring and recurrence monitoring), target disease indications (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, gastric cancer, pancreatic cancer, ovarian cancer, and others), end users (hospitals, research institutes and others) and key geographical regions (the US, the UK, Germany, Italy, Spain, France, Japan, Australia, China, India, and Rest of the World).

Chapter 13 presents insights from the survey conducted on stakeholders involved in the development of different types of liquid biopsies and other non-invasive tests. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products and the associated commercial potential.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Shibichakravarthy Kannan (Founder and CEO, Theranosis Life Sciences), Abizar Lakdawalla (Founder, ProXeom), Philippe Nore (CEO and Co-founder, MiNDERA Corporation), Frank Szczepanski (President and CEO, IVDiagnostics), Mark Li (CEO, Resolution Bioscience), Joachim Fluhrer (Founder and Medical Director, Genostics), Brad Walsh (CEO, Minomic International), Anton Iliuk (President and Chief Technology Officer, Tymora Analytical Operations), Burkhard Jansen (Chief Medical Officer, DermTech), Christer Ericsson (Chief Scientific Officer, iCellate Medical), Jake Micallef (Chief Scientific Officer, VolitionRx), Nathalie Bernard (Marketing Director, OncoDNA), Riccardo Razzini (Sales and Marketing Manager, LCM Genect), and Peter French (Strategic Technology Advisor, Sienna Cancer Diagnostics).

Chapter 15 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the cancer diagnostics.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease 
3.3. Importance of Early Cancer Detection 
3.4. Cancer Screening and Diagnosis
 
3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.1.1. Fine Needle Aspiration Biopsy
3.5.1.2. Core Needle Biopsy
3.5.1.3. Vacuum-Assisted Biopsy
3.5.1.4. Image-Guided Biopsy
3.5.1.5. Sentinel Node Biopsy
3.5.1.6. Surgical Biopsy
3.5.1.7. Endoscopic Biopsy
3.5.1.8. Bone Marrow Biopsy
3.5.2. Endoscopy
 
3.6. Need for Non-Invasive Approaches 
 
3.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
3.7.1. Circulating Tumor Cells
3.7.2. Circulating Tumor DNA
3.7.3. Exosomes
 
3.8. Costs and Benefits Associated with Liquid Bi0psy and Non-Invasive Tests
3.9. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
3.10. Challenges Associated with Non-Invasive Cancer Diagnostics
3.11. Future Perspectives
 
4. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerized Tomography (CT) Scan
4.2.5. Integrated Positron Emission Tomography (PET)-CT Scan
4.2.6. Ultrasound
4.2.7. X-ray Radiography (Barium Enema)
 
4.3. Screening Assays
4.3.1. Circulating Tumor Marker Test
4.3.2. Digital Rectal Exam (DRE)
4.3.3. Fecal Occult Blood Test (FOBT)
4.3.4. Multigated Acquisition (MUGA) Scan
4.3.5. Papanicolaou Test and Human Papilloma Virus Test
 
4.4. Advanced Non-Invasive Approaches
4.4.1. Cytogenetic / Gene Expression Studies
4.4.2. Molecular Signature-based Non-Invasive Methods
4.4.3. Saliva-based Oral Cancer Diagnostics
4.4.4. Vital Staining
4.4.5. Optical Biopsy
4.4.6. Other Diagnostic Techniques
 
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Liquid Biopsy Products: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size and Geographical Location
5.2.3. Leading Players
5.2.4. Analysis by Geography
 
5.3.  Liquid Biopsy Products: List of Available / Under Development Products
5.3.1. Analysis by Status of Development
5.3.2. Analysis by Type of Product
5.3.3. Analysis by Application Area  
5.3.4. Analysis by Target Cancer Indication
5.3.5. Analysis by Type of Tumor Marker
5.3.6. Analysis by End User
5.3.7. Analysis by Turnaround Time
 
5.4. Liquid Biopsy Products: List of Other Products, Kits and Consumables
5.5. Liquid Biopsy Products: List of Contract Service Providers
 
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Amoy Diagnostics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Liquid Biopsy Product Portfolio
6.2.4. Recent Developments and Future Outlook
 
6.3. DiaCarta
6.3.1. Company Overview
6.3.2. Liquid Biopsy Product Portfolio
6.3.3. Recent Developments and Future Outlook
 
6.4. HaploX
6.4.1. Company Overview
6.4.2. Liquid Biopsy Product Portfolio
6.4.3. Recent Developments and Future Outlook
 
6.5. NeoGenomics
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Liquid Biopsy Product Portfolio
6.5.4. Recent Developments and Future Outlook
 
6.6. QIAGEN
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Liquid Biopsy Product Portfolio
6.6.4. Recent Developments and Future Outlook
 
6.7. Swift Biosciences
6.7.1. Company Overview
6.7.2. Liquid Biopsy Product Portfolio
6.7.3. Recent Developments and Future Outlook
 
6.8. Sysmex Inostics
6.8.1. Company Overview
6.8.2. Liquid Biopsy Product Portfolio
6.8.3. Recent Developments and Future Outlook
 
6.9. Thermo Fisher Scientific
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Liquid Biopsy Product Portfolio
6.9.4. Recent Developments and Future Outlook
 
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
 
7.3. List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Tumor Marker
7.3.4. Analysis by Target Cancer Indication
7.3.5. Analysis by Type of Partner
7.3.6. Most Active Players: Analysis by Number of Partnerships
7.3.7. Regional Analysis
7.3.7.1. Intercontinental and Intracontinental Agreements
 
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
 
8.3. List of Funding and Investment Instances
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Target Cancer Indication 
8.3.5. Analysis by Type of Tumor Marker
8.3.6. Most Active Players: Analysis by Amount Invested
8.3.7. Most Active Investors: Analysis by Number of Funding Instances
8.3.8. Regional Analysis by Amount Invested
 
8.4. Concluding Remarks
 
9. LIQUID BIOPSY: INITIATIVES OF BIG PHARMA PLAYERS
9.1. Chapter Overview
9.2. Top Pharmaceutical Companies
9.2.1. Analysis by Status of Development
9.2.2. Analysis by Type of Tumor Marker
9.2.3. Analysis by Application Area
9.2.4. Analysis by Target Cancer Indication
 
10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Scoring Criteria and Key Assumptions
10.4. Potential Strategic Acquisition Targets in North America
10.5. Potential Strategic Acquisition Targets in Europe
10.6. Potential Strategic Acquisition Targets in Asia-Pacific / Rest of the World
10.7. Concluding Remarks
 
11. OTHER NON-INVASIVE CANCER DIAGNOSTICS
11.1. Chapter Overview
11.2. Non-Blood-based Biomarker Detection Tests
11.3. FOBT and Fecal Immunochemical Tests (FIT)
11.4. Pigmented Lesion Assays
11.5. Stool DNA (sDNA)-based Tests
11.6. Volatile Organic Compound (VOC) Detection Tests
11.7. Other Non-Invasive Cancer Diagnostics: Market Landscape
 
12. MARKET SIZING AND OPPORTUNITY ANALYSIS 
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
 
12.3. Global Non-Invasive Cancer Diagnostics Market, 2019-2030
 
12.3.1. Global Liquid Biopsy Market, 2019-2030
12.3.1.1. Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030
12.3.1.1.1. Global Liquid Biopsy Market for Early Diagnosis, 2019-2030
12.3.1.1.2. Global Liquid Biopsy Market for Patient Monitoring, 2019-2030
12.3.1.1.3. Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030
 
12.3.1.2. Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030
12.3.1.2.1. Global Liquid Biopsy Market for Breast Cancer, 2019-2030
12.3.1.2.2. Global Liquid Biopsy Market for Lung Cancer, 2019-2030
12.3.1.2.3. Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030
12.3.1.2.4. Global Liquid Biopsy Market for Prostate Cancer, 2019-2030
12.3.1.2.5. Global Liquid Biopsy Market for Bladder Cancer, 2019-2030
12.3.1.2.6. Global Liquid Biopsy Market for Melanoma, 2019-2030
12.3.1.2.7. Global Liquid Biopsy Market for Gastric Cancer, 2019-2030
12.3.1.2.8. Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030
12.3.1.2.9. Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030
   
12.3.1.3. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030
12.3.1.3.1. Global Liquid Biopsy Market for ctDNA, 2019-2030
12.3.1.3.2. Global Liquid Biopsy Market for cfDNA, 2019-2030
12.3.1.3.3. Global Liquid Biopsy Market for CTCs, 2019-2030
12.3.1.3.4. Global Liquid Biopsy Market for Exosomes, 2019-2030
12.3.1.3.5. Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030
 
12.3.1.4. Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030
12.3.1.4.1. Global Liquid Biopsy Market for Blood, 2019-2030
12.3.1.4.2. Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)
 
12.3.1.5. Global Liquid Biopsy Market: Distribution by End User, 2019-2030
12.3.1.5.1. Global Liquid Biopsy Market for Hospitals, 2019-2030
12.3.1.5.2. Global Liquid Biopsy Market for Research Institutes, 2019-2030
12.3.1.5.3. Global Liquid Biopsy Market for Other End Users, 2019-2030
 
12.3.1.6. Global Liquid Biopsy Market: Distribution by Geography, 2019-2030
12.3.1.6.1 Liquid Biopsy Market in the US, 2019-2030
12.3.1.6.2 Liquid Biopsy Market in the UK, 2019-2030
12.3.1.6.3 Liquid Biopsy Market in Germany, 2019-2030
12.3.1.6.4 Liquid Biopsy Market in France, 2019-2030
12.3.1.6.5 Liquid Biopsy Market in Italy, 2019-2030
12.3.1.6.6 Liquid Biopsy Market in Spain, 2019-2030
12.3.1.6.7 Liquid Biopsy Market in Japan, 2019-2030
12.3.1.6.8 Liquid Biopsy Market in China, 2019-2030
12.3.1.6.9 Liquid Biopsy Market in India, 2019-2030
12.3.1.6.10 Liquid Biopsy Market in Australia, 2019-2030
 
12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2019-2030
 
13. SURVEY INSIGHTS
13.1. Chapter Overview
13.2. Company Specifics of Respondents
13.3. Designation of Respondents
13.4. Type of Product Portfolio
13.5. Types of Products / Services Offered
13.6. Application Area
13.7. Status of Development of the Products
13.8. Likely Market Size
 
14. CONCLUSION
14.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care in the Field of Oncology
14.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer Management
14.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis
14.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range of Applications
14.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different Geographies
14.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further Strengthen the Ongoing Innovation
14.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential
14.8. Primarily Led by Liquid Biopsy, the Non-Invasive Cancer Diagnostics Market has Emerged as a Multi-Billion Dollar Market
 
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Interview Transcript: Shibichakravarthy Kannan, Founder & Chief Executive Officer, Theranosis Life Sciences
15.3. Interview Transcript: Anton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations
15.4. Interview Transcript: Peter French, Strategic Technology Advisor, Sienna Cancer Diagnostics
15.5. Interview Transcript: Joachim Fluhrer, Founder and Medical Director, Genostics
15.6. Interview Transcript: Brad Walsh, Chief Executive Officer, Minomic International
15.7. Interview Transcript: Catalina Vasquez, Chief Operating Officer, Nanostics
15.8. Interview Transcript: Burkhard Jansen, Chief Medical Officer, DermTech
15.9. Interview Transcript: Frank Szczepanski, President and CEO, IVDiagnostics
15.10. Interview Transcript: Riccardo Razzini, Sales and Marketing Manager, LCM Genect
15.11. Interview Transcript: Nathalie Bernard, Marketing Director, OncoDNA
15.12. Interview Transcript: Abizar Lakdawalla, Founder, Proxeom 
15.13. Interview Transcript: Mark Li, CEO, Resolution Bioscience
15.14. Interview Transcript: Christer Ericsson, Chief Scientific Officer, iCellate Medical
15.15. Interview Transcript: Philippe Nore, CEO and Co-founder, MiNDERA 
15.16. Interview Transcript: Jake Micallef, Chief Scientific Officer, VolitionRx
 
16. APPENDIX 1: TABULATED DATA
  
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Worldwide Incidence of Cancer: Distribution by Indication
Figure 3.2 Lung Cancer: Estimated New Cases in 2018 (in Thousands)
Figure 3.3 Breast Cancer: Estimated New Cases in 2018 (in Thousands)
Figure 3.4 Colorectal Cancer: Estimated New Cases in 2018 (in Thousands)
Figure 3.5 Factors Determining Useful Cancer Screening
Figure 3.6 Conventional Cancer Diagnosis Methods
Figure 3.7 Disadvantages of Conventional Cancer Diagnosis Methods
Figure 3.8 Circulating Biomarkers for Cancer Detection
Figure 3.9 Traditional Biopsy: Process Flow
Figure 3.10 Non-Invasive Biopsy: Process Flow
Figure 3.11 Non-Invasive Cancer Diagnostics: Year-wise Distribution of Patents
Figure 4.1 Broad Categories of Non-Invasive Cancer Screening and Diagnostics
Figure 4.2 Types of Diagnostic Imaging
Figure 4.3 Types of Screening Assays
Figure 4.4 Types of Advanced Non-Invasive Approaches for Cancer Diagnosis
Figure 5.1 Liquid Biopsy Developers: Distribution by Year of Establishment
Figure 5.2 Liquid Biopsy Developers: Distribution by Company Size and Geographical Location
Figure 5.3 Liquid Biopsy Developers: Leading Players
Figure 5.4 Liquid Biopsy Developers: Distribution by Geographical Location of Developer
Figure 5.5 Liquid Biopsy Products: Distribution by Status of Development
Figure 5.6 Liquid Biopsy Products: Distribution by Type of Product
Figure 5.7 Liquid Biopsy Products: Distribution by Application Area  
Figure 5.8 Venn Diagram Representation: Distribution by Application Area
Figure 5.9 Liquid Biopsy Products: Distribution by Target Cancer Indication
Figure 5.10 Liquid Biopsy Products: Distribution by Type of Tumor Marker
Figure 5.11 Liquid Biopsy Products: Distribution by Type of Tumor Marker and Application Area
Figure 5.12 Liquid Biopsy Products: Distribution by End User
Figure 5.13 Liquid Biopsy Products: Distribution by Turnaround Time
Figure 6.1 Amoy Diagnostics: Annual Revenues, FY2016 - FY2018 (CNY Million)
Figure 6.2 NeoGenomics: Annual Revenues, FY2014 - FY2018 (USD Million)
Figure 6.3 QIAGEN: Annual Revenues, FY2014 - FY2018 (USD Billion)
Figure 6.4 Thermo Fisher Scientific: Annual Revenues, FY2014 - FY2018 (USD Billion)
Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2019
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership (2016-2019)
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Tumor Marker
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Tumor Marker
Figure 7.6 Partnerships and Collaborations: Distribution by Target Cancer Indication
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Target Cancer Indication
Figure 7.8 Partnerships and Collaborations: Distribution by Year and Type of Partners
Figure 7.9 Partnerships and Collaborations: Most Active Players 
Figure 7.10 Partnerships and Collaborations: Regional Distribution
Figure 7.11 Partnerships and Collaborations: Intercontinental and Intracontinental Partnerships
Figure 8.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment of Receiving Companies, 2015-2019
Figure 8.2 Funding and Investment Analysis: Cumulative Year-wise Trend, 2015-2019
Figure 8.3 Funding and Investment Analysis: Cumulative Amount Invested, 2015-2019 (USD Million)
Figure 8.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2015-2019
Figure 8.5 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2015-2019 (USD Million)
Figure 8.6 Funding and Investment Analysis: Summary of Investments, 2015-2019 (USD Million)
Figure 8.7 Funding and Investment Analysis: Distribution by Instances Across Different Types of Indications
Figure 8.8 Funding and Investment Analysis: Distribution by Number of Instances and Amount Invested Across Different Types of Tumor Marker 
Figure 8.9 Funding and Investment Analysis: Most Active Players, 2015 – 2019 (USD Million) 
Figure 8.10 Funding and Investment Analysis: Most Active Investors
Figure 8.11 Funding and Investment Analysis: Distribution by Geography 
Figure 8.12 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 8.13 Funding and Investment Summary, 2015-2019 (USD Million)
Figure 9.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 9.2 Big Pharma Players: Analysis by Status of Development
Figure 9.3 Big Pharma Players: Analysis by Type of Tumor Marker
Figure 9.4 Big Pharma Players: Analysis by Type of Application Area
Figure 9.5 Big Pharma Players: Analysis by Target Cancer Indication
Figure 10.1 Likely Acquisition Targets: Geographical Distribution
Figure 12.1 Global Non-Invasive Cancer Diagnostics Market, 2019-2030 (USD Million)
Figure 12.2 Global Liquid Biopsy Market, 2019-2030 (USD Million)
Figure 12.3 Global Liquid Biopsy Market: Distribution by Application Area, 2019, 2030 
Figure 12.4 Global Liquid Biopsy Market for Early Diagnosis, 2019-2030 (USD Million)
Figure 12.5 Global Liquid Biopsy Market for Patient Monitoring, 2019-2030 (USD Million)
Figure 12.6 Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030 (USD Million)
Figure 12.7 Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019, 2030
Figure 12.8 Global Liquid Biopsy Market for Breast Cancer, 2019-2030 (USD Million)
Figure 12.9 Global Liquid Biopsy Market for Lung Cancer, 2019-2030 (USD Million)
Figure 12.10 Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030 (USD Million)
Figure 12.11 Global Liquid Biopsy Market for Prostate Cancer, 2019-2030 (USD Million)
Figure 12.12 Global Liquid Biopsy Market for Bladder Cancer, 2019-2030 (USD Million)
Figure 12.12 Global Liquid Biopsy Market for Melanoma, 2019-2030 (USD Million)
Figure 12.14 Global Liquid Biopsy Market for Gastric Cancer, 2019-2030 (USD Million)
Figure 12.15 Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030 (USD Million)
Figure 12.16 Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030 (USD Million)
Figure 12.17 Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019, 2030
Figure 12.18 Global Liquid Biopsy Market for ctDNA, 2019-2030 (USD Million)
Figure 12.19 Global Liquid Biopsy Market for cfDNA, 2019-2030 (USD Million)
Figure 12.20 Global Liquid Biopsy Market for CTCs, 2019-2030 (USD Million)
Figure 12.21 Global Liquid Biopsy Market for Exosomes, 2019-2030 (USD Million)
Figure 12.22 Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030 (USD Million)
Figure 12.23 Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019, 2030
Figure 12.24 Global Liquid Biopsy Market for Blood, 2019-2030 (USD Million)
Figure 12.25 Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Million)
Figure 12.26 Global Liquid Biopsy Market: Distribution by End User, 2019, 2030 
Figure 12.27 Global Liquid Biopsy Market for Hospitals, 2019-2030 (USD Million)
Figure 12.28 Global Liquid Biopsy Market for Research Institutes, 2019-2030 (USD Million)
Figure 12.29 Global Liquid Biopsy Market for Other End Users, 2019-2030 (USD Million)
Figure 12.30 Global Liquid Biopsy Market: Distribution by Geography, 2019, 2030 
Figure 12.31 Liquid Biopsy Market in the US, 2019-2030, By Value (USD Million)
Figure 12.32 Liquid Biopsy Market in the US, By Volume, 2019-2030 (Million Units)
Figure 12.33 Liquid Biopsy Market in the UK, By Value, 2019-2030 (USD Million)
Figure 12.34 Liquid Biopsy Market in the UK, By Volume, 2019-2030 (Million Units)
Figure 12.35 Liquid Biopsy Market in Germany, By Value, 2019-2030 (USD Million)
Figure 12.36 Liquid Biopsy Market in Germany, By Volume, 2019-2030 (Million Units)
Figure 12.37 Liquid Biopsy Market in France, By Value, 2019-2030 (USD Million)
Figure 12.38 Liquid Biopsy Market in France, By Volume, 2019-2030 (Million Units)
Figure 12.39 Liquid Biopsy Market in Italy, By Value, 2019-2030 (USD Million)
Figure 12.40 Liquid Biopsy Market in Italy, By Volume, 2019-2030 (Million Units)
Figure 12.41 Liquid Biopsy Market in Spain, By Value, 2019-2030 (USD Million)
Figure 12.42 Liquid Biopsy Market in Spain, By Volume, 2019-2030 (Million Units)
Figure 12.43 Liquid Biopsy Market in Japan, By Value, 2019-2030 (USD Million)
Figure 12.44 Liquid Biopsy Market in Japan, By Volume, 2019-2030 (Million Units)
Figure 12.45 Liquid Biopsy Market in China, By Value, 2019-2030 (USD Million)
Figure 12.46 Liquid Biopsy Market in China, By Volume, 2019-2030 (Million Units)
Figure 12.47 Liquid Biopsy Market in India, By Value, 2019-2030 (USD Million)
Figure 12.48 Liquid Biopsy Market in India, By Volume, 2019-2030 (Million Units)
Figure 12.49 Liquid Biopsy Market in Australia, By Value, 2019-2030 (USD Million)
Figure 12.50 Liquid Biopsy Market in Australia, By Volume, 2019-2030 (Million Units)
Figure 12.51 Other Non-Invasive Cancer Diagnostics Market: 2019-2030 (USD Million)
Figure 13.1 Survey Insights: Distribution of Respondents by Year of Establishment of Company
Figure 13.2 Survey Insights: Distribution of Respondents by Company Size
Figure 13.3 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-wise)
Figure 13.4 Survey Insights: Distribution by Designation and Seniority Level
Figure 13.5 Survey Insights: Distribution by Type of Product Portfolio
Figure 13.6 Survey Insights: Distribution by Type of Products / Services Offered
Figure 13.7 Survey Insights: Distribution by Application Area
Figure 13.8 Survey Insights: Distribution by Status of Development of the Products
Figure 13.9 Survey Insights: Likely Liquid Biopsy Market Size (2030)
Figure 13.10 Survey Insights: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
Figure 14.1 Non-Invasive Cancer Diagnostics Market (USD Million), 2019, 2025 and 2030

List of Tables

Table 3.1 Survival on Early Diagnosis of Cancer
Table 3.2 Cost of Biopsy for Different Cancer Indications (in USD)
Table 3.3 Common Endoscopic Procedures
Table 4.1 Examples of Tumor Markers
Table 5.1 Liquid Biopsy Products: Developer Overview
Table 5.2 Liquid Biopsy Products: List of Available / Under Development Products
Table 5.3 Liquid Biopsy Products: List of Additional Products
Table 5.4 Liquid Biopsy Products: List of Other Kits and Consumables
Table 5.5 Liquid Biopsy Products: List of Contract Service Providers
Table 6.1 Non-Invasive Cancer Diagnostics: List of Profiled Companies
Table 6.2 Amoy Diagnostics: Company Snapshot
Table 6.3 Amoy Diagnostics: Product Portfolio
Table 6.4 Amoy Diagnostics: Recent Developments and Future Outlook
Table 6.5 DiaCarta: Company Snapshot
Table 6.6 DiaCarta: Product Portfolio
Table 6.7 DiaCarta: Recent Developments and Future Outlook
Table 6.8 HaploX: Company Snapshot
Table 6.9 HaploX: Product Portfolio
Table 6.10 HaploX: Recent Developments and Future Outlook
Table 6.11 NeoGenomics: Company Snapshot
Table 6.12 NeoGenomics: Product Portfolio
Table 6.13 NeoGenomics: Recent Developments and Future Outlook
Table 6.14 QIAGEN: Company Snapshot
Table 6.15 QIAGEN: Product Portfolio
Table 6.16 QIAGEN: Recent Developments and Future Outlook
Table 6.17 Swift Biosciences: Company Snapshot
Table 6.18 Swift Biosciences: Product Portfolio
Table 6.19 Swift Biosciences: Recent Developments and Future Outlook
Table 6.20 Sysmex Inostics: Company Snapshot
Table 6.21 Sysmex Inostics: Product Portfolio
Table 6.22 Sysmex Inostics: Recent Developments and Future Outlook
Table 6.23 Thermo Fisher Scientific: Company Snapshot
Table 6.24 Thermo Fisher Scientific: Product Portfolio
Table 6.25 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 7.1 Non-Invasive Cancer Diagnostics: Partnerships and Collaborations, 2016-2019
Table 8.1 Non-Invasive Cancer Diagnostics Market: Funding and Investments, 2015-2019
Table 8.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 North America: Most Likely Partners for Acquisition
Table 10.2 Europe: Most Likely Partners for Acquisition
Table 10.3 Asia-Pacific / Rest of the World: Most Likely Partners for Acquisition
Table 11.1 Other Non-Invasive Cancer Diagnostics: Market Landscape
Table 13.1 Survey Insights: Overview of Respondents
Table 13.2 Survey Insights: Designation and Seniority Levels
Table 13.3 Survey Insights: Type of Product Portfolio
Table 13.4 Survey Insights: Type of Products / Services Offered
Table 13.5 Survey Insights: Application Area
Table 13.6 Survey Insights: Status of Development of the Products
Table 13.7 Survey Insights: Likely Liquid Biopsy Market Size (2030)
Table 13.8 Survey Insights: Likely Other Non-Invasive Cancer Diagnostics Market Size
Table 16.1 Liquid Biopsy Developers: Distribution by Year of Establishment
Table 16.2 Liquid Biopsy Developers: Distribution by Company Size and Geographical Location
Table 16.3 Liquid Biopsy Developers: Leading Players
Table 16.4 Liquid Biopsy Products: Distribution by Status of Development
Table 16.5 Liquid Biopsy Products: Distribution by Type of Product
Table 16.6 Liquid Biopsy Products: Distribution by Application Area
Table 16.7 Liquid Biopsy Products: Distribution by Target Cancer Indication
Table 16.8 Liquid Biopsy Products: Distribution by Type of Tumor Marker
Table 16.9 Liquid Biopsy Products: Distribution by End User
Table 16.10 Liquid Biopsy Products: Distribution by Turnaround Time
Table 16.11 Amoy Diagnostics: Annual Revenues, FY2016-FY2018 (CNY Million)
Table 16.12 NeoGenomics: Annual Revenues, FY2014 - FY2018 (EUR Million)
Table 16.13 QIAGEN: Annual Revenues, FY2014 - FY2018 (EUR Billion)
Table 16.14 Thermo Fisher Scientific: Annual Revenues, FY2014 - FY2018 (EUR Billion)
Table 16.15 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2019
Table 16.16 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.17 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2016-2019
Table 16.18 Partnerships and Collaborations: Distribution by Type of Tumor Marker
Table 16.19 Partnerships and Collaborations: Distribution by Target Cancer Indication
Table 16.20 Partnerships and Collaborations: Distribution by Year and Type of Partners
Table 16.21 Partnerships and Collaborations: Most Active Players
Table 16.22 Partnerships and Collaborations: Regional Distribution
Table 16.23 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-2019
Table 16.24 Funding and Investment Analysis: Cumulative Amount Invested, 2015-2019 (USD Million)
Table 16.25 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2015-2019
Table 16.26 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2015-2019 (USD Million)
Table 16.27 Funding and Investments: Distribution by Number of Instances and Amount Invested Across Different Types of Tumor Marker
Table 16.28 Funding and Investment Analysis: Most Active Players, 2015-2019 (USD Million) 
Table 16.29 Funding and Investment Analysis: Most Active Investors 
Table 16.30 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 16.31 Global Non-Invasive Cancer Diagnostics Market, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.32 Global Liquid Biopsy Market, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.33 Global Liquid Biopsy Market: Distribution by Application Area, 2019, 2030
Table 16.34 Global Liquid Biopsy Market for Early Diagnosis, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.35 Global Liquid Biopsy Market for Patient Monitoring, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.36 Global Liquid Biopsy Market for Recurrence Monitoring, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.37 Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019, 2030
Table 16.38 Global Liquid Biopsy Market for Breast Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.39 Global Liquid Biopsy Market for Lung Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.40 Global Liquid Biopsy Market for Colorectal Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.41 Global Liquid Biopsy Market for Prostate Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.42 Global Liquid Biopsy Market for Bladder Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.43 Global Liquid Biopsy Market for Melanoma, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.44 Global Liquid Biopsy Market for Gastric Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.45 Global Liquid Biopsy Market for Pancreatic Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.46 Global Liquid Biopsy Market for Ovarian Cancer, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.47 Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019, 2030
Table 16.48 Global Liquid Biopsy Market for ctDNA, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.49 Global Liquid Biopsy Market for cfDNA, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.50 Global Liquid Biopsy Market for CTCs, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.51 Global Liquid Biopsy Market for Exosomes, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.52 Global Liquid Biopsy Market for Other Tumor Markers, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.53 Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019, 2030
Table 16.54 Global Liquid Biopsy Market for Blood, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.55 Global Liquid Biopsy Market for Other Body Fluids, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.56 Global Liquid Biopsy Market: Distribution by End User, 2019, 2030
Table 16.57 Global Liquid Biopsy Market for Hospitals, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.58 Global Liquid Biopsy Market for Research Institutes, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.59 Global Liquid Biopsy Market for Other End Users, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.60 Global Liquid Biopsy Market: Distribution by Geography, 2019, 2030
Table 16.61 Liquid Biopsy Market in the US, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.62 Liquid Biopsy Market in the US, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.63 Liquid Biopsy Market in the UK, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.64 Liquid Biopsy Market in the UK, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.65 Liquid Biopsy Market in Germany, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.66 Liquid Biopsy Market in Germany, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.67 Liquid Biopsy Market in France, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.68 Liquid Biopsy Market in France, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.69 Liquid Biopsy Market in Italy, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.70 Liquid Biopsy Market in Italy, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.71 Liquid Biopsy Market in Spain, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.72 Liquid Biopsy Market in Spain, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.73 Liquid Biopsy Market in Japan, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.74 Liquid Biopsy Market in Japan, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.75 Liquid Biopsy Market in China, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.76 Liquid Biopsy Market in China, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.77 Liquid Biopsy Market in India, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.78 Liquid Biopsy Market in India, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.79 Liquid Biopsy Market in Australia, By Value, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.80 Liquid Biopsy Market in Australia, By Volume, Conservative, Base, and Optimistic Scenario, 2019-2030 (Million Units)
Table 16.81 Other Non-Invasive Cancer Diagnostics Market, Conservative, Base, and Optimistic Scenario, 2019-2030 (USD Million)
Table 16.82 Survey Insights: Distribution of Respondents by Year of Establishment of Company
Table 16.83 Survey Insights: Distribution of Respondents by Company Size
Table 16.84 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-wise)
Table 16.85 Survey Insights: Distribution by Designation and Seniority Level
Table 16.86 Survey Insights: Distribution by Type of Product Portfolio
Table 16.87 Survey Insights: Distribution by Type of Products / Services Offered
Table 16.88 Survey Insights: Distribution by Application Area
Table 16.89 Survey Insights: Distribution by Status of Development of the Products
Table 16.90 Survey Insights: Likely Liquid Biopsy Market Size (2030)
Table 16.91 Survey Insights: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
Table 16.92 Non-Invasive Cancer Diagnostics Market (USD Million), 2019, 2025 and 2030

List of Companies

  1. 360 Capital Partners
  2. 4D Lifetec
  3. 50K Ventures
  4. 5AM Ventures
  5. 6 Dimensions Capital
  6. A&G Pharmaceutical
  7. Abbott
  8. Abcodia
  9. Accu Reference Medical Lab
  10. AccuraGen
  11. Ackermans & van Haaren
  12. Acobiom
  13. Acousys Biodevices
  14. Active Motif
  15. Acuamark Diagnostics
  16. ADC Therapeutics
  17. Addario Lung Cancer Medical Institute
  18. Admera Health
  19. Advanced Wave Sensors 
  20. Affymetrix
  21. AGCT
  22. Agena Bioscience
  23. Agilent Technologies
  24. Agiomix
  25. Ahren Innovation Capital
  26. Alabama Capital Network
  27. Albert & Annas Minne Foundation
  28. Alentia Capital Alternativo
  29. Alexandria Venture Investments
  30. Alliance Global
  31. Ally Bridge Group
  32. Alychlo
  33. Amadix
  34. AMAL Therapeutics
  35. Amazon
  36. Amedes Group
  37. Amer International Group
  38. America’s Choice Provider Network
  39. American Bio Services
  40. Amgen
  41. Amoy Diagnostics
  42. Anchor Molecular
  43. ANCON Medical
  44. Andreessen Horowitz
  45. ANGLE
  46. Anixa Biosciences
  47. Annoroad Gene Technology
  48. Anpac Bio
  49. Anthill Ventures
  50. Apostle
  51. Arboretum Ventures
  52. ARCH Venture Partners
  53. ArcherDX
  54. ARNA Genomics
  55. Arquer Diagnostics
  56. ArrayGenomics
  57. Arrow Diagnostics
  58. Artiman Ventures
  59. ARUP Laboratories
  60. ASB Ventures 
  61. Asia Genomics
  62. ASPiRA LABS
  63. AstraZeneca
  64. Astrimmune
  65. Asuragen
  66. Aurum Ventures 
  67. AVIVA Biosciences
  68. Balderton Capital
  69. Bangkok Molecular Genetics
  70. BARD1 Life Sciences
  71. BeAble Capital
  72. BeaconLBS
  73. Bellwether Bio
  74. Best Med Opinion
  75. Beth Israel Deaconess Medical Center
  76. Betta Pharmaceuticals
  77. Bezos Expeditions
  78. BGI Genomics
  79. Bill & Melinda Gates Foundation
  80. Biocartis
  81. Biocept
  82. BioChain
  83. Biodesix
  84. BioDiscovery
  85. Bioeconomy Capital
  86. BioFluidica
  87. BIOHAL
  88. BioHisto Maroc
  89. Biolidics
  90. Biological Dynamics
  91. BioMarCare Technologies
  92. BioMark Diagnostics
  93. BiomaRx
  94. BIOPROGNOS
  95. Bio-Rad Laboratories
  96. Biosearch Technologies
  97. BioSequence
  98. BioVeda China Fund (BVCF)
  99. BioVendor
  100. BioView
  101. Bioyong Technology
  102. BloodPAC 
  103. Blue Pool Capital
  104. Bluestar Genomics
  105. BNO BIO
  106. Boehringer Ingelheim
  107. Boreal Genomics
  108. Boston Children’s Hospital
  109. Breath Diagnostics
  110. BrightEdge Ventures
  111. Bristol-Myers Squibb
  112. BSN
  113. Burning Rock Biotech
  114. Cambridge Epigenetix
  115. Cambridge Innovation Capital
  116. Cambridge University
  117. CANCER-ID
  118. Canostix
  119. Capio Biosciences
  120. Capital Research and Management
  121. CareFirst BlueCross BlueShield
  122. Caris Life Sciences
  123. Cathay Fortune International
  124. CDBI Partners
  125. Celgene
  126. CellMax Life
  127. Celsee
  128. Checkmate Pharmaceuticals
  129. China Biotech Services
  130. China Merchants Securities International
  131. Chronix Biomedical
  132. CIRCULOGENE
  133. Cirina
  134. Cleveland Diagnostics
  135. Clinical Genomics
  136. Clinomics
  137. CloudHealth Genomics
  138. Cloudstone Venture Fund
  139. Co-Diagnostics
  140. Colorectal Cancer Alliance
  141. ConquerX
  142. CORE Diagnostics
  143. Cornerstone Total Return Fund
  144. Cowin Venture Capital
  145. CPH Capital
  146. CryoGene
  147. Cyclomics
  148. Cynvenio-Livzon Diagnostics
  149. Cytofind Diagnostics
  150. Cytosystems
  151. Data Collective
  152. Datar Cancer Genetics
  153. Decheng Capital
  154. Delee
  155. Denlux Capital
  156. DermTech
  157. DiaCarta
  158. DiaDx
  159. Diagnolita
  160. Diagnostics Development Hub
  161. DIAN Diagnostics
  162. Diatech Pharmacogenetics
  163. DiuVita Diagnostics
  164. DNA Labs India
  165. Dow Biomedica
  166. DT Capital
  167. Durviz
  168. EarlyDx
  169. EDP Biotech
  170. EKF Diagnostics
  171. Elypta
  172. EONE Diagnomics Genome Center
  173. Epic Sciences
  174. Epigenomics
  175. Eurobio Scientific
  176. Eurofins Biomnis
  177. European Association for Predictive, Preventive & Personalised Medicine
  178. European Commission
  179. European Organisation for Research and Treatment of Cancer
  180. Exact Sciences
  181. Exalt Diagnostics
  182. ExBiome
  183. Exosome Diagnostics
  184. Exosomics
  185. Expedeon
  186. Fårö Capital
  187. Flagship Biosciences 
  188. Fluxion Biosciences
  189. Fortune Fountain Capital
  190. Fosun Pharmaceutical
  191. Foundation Medicine
  192. Fountain Medical Development
  193. Fox Chase Cancer Center
  194. Franklin Templeton Investments
  195. Frederick National Laboratory for Cancer Research
  196. Freenome
  197. Fudan-Taizhou Institute of Health Sciences
  198. GEM Global Yield Fund
  199. GeneCast Biotechnology
  200. Generation Investment Management
  201. Geneseq Biosciences
  202. Genetics Research
  203. Genetracer Biotech
  204. GENEWIZ
  205. GENEXT
  206. Genomenon
  207. Genomic Health
  208. Genomics England
  209. Genomictree
  210. Genoptix
  211. Genostics
  212. GILUPI
  213. Glycanostics
  214. Good Health Capital
  215. GRAIL
  216. Great Lakes New England Clinical Validation Center
  217. Green Pine Capital Partners
  218. Guangzhou Wondfo Biotech
  219. Guardant Health
  220. Gunnar Nilsson Cancer Foundation
  221. GV
  222. Hadean Ventures
  223. HaploX
  224. HarlePhil Ventures
  225. HDFC
  226. HealthCor Partners Management
  227. HEDA Ventures
  228. Helice Genomic Sciences
  229. Helsinn Investment Fund
  230. Highlight Capital
  231. Hillhouse Capital Group
  232. hrmed.tech
  233. HuangPu River Capital (HPR)
  234. Hummingbird Diagnostics
  235. Hvidovre Hospital
  236. Hyderabad Angels
  237. ICBC International
  238. iCellate Medical
  239. Idinvest Partners
  240. iGenetic Diagnostics
  241. Ikonisys
  242. Illumina
  243. Immodulon Therapeutics
  244. Impact Lab
  245. Imperial Innovations
  246. IncellDx
  247. Indian Angel Network
  248. Inivata
  249. Innovative Diagnostic Laboratory
  250. Innovatus Capital Partners
  251. Inova Strategic Investments
  252. Inovio Pharmaceuticals
  253. Institut Jules Bordet
  254. Integrated Diagnostics Holdings
  255. International Medical Center
  256. Interpace Diagnostics
  257. Intezyne
  258. Inventures
  259. Invitek Molecular
  260. Invoke Capital
  261. IP Group
  262. BIO.be
  263. IPS Genomix
  264. IV Diagnostics
  265. Janssen Diagnostics
  266. Jennison Associates
  267. Johnson & Johnson Innovation
  268. Jointown Pharmaceutical Group
  269. JTS Health Partners
  270. Junson Capital
  271. Kaiser Permanente Ventures
  272. KEODES
  273. Kexin Capital
  274. LABLAB
  275. Laboratory for Advanced Medicine
  276. Lariat Biosciences
  277. Levine Cancer Institute 
  278. Lexent Bio
  279. LifeArc
  280. LifeX
  281. Lilly Asia Ventures
  282. Limitless Earth
  283. Liquid Biotech
  284. Lonza
  285. Loyal Valley Capital
  286. LU Holding
  287. Lucence Diagnostics
  288. LungLife AI
  289. MagBio Genomics
  290. Martell Biosystems
  291. Maryland Venture Fund
  292. Mascots Medical and Laboratory Center
  293. Massive Genomics
  294. Matrix Partners China
  295. Mayo Clinic
  296. McKesson Ventures
  297. MDNA Life Sciences
  298. MDxHealth
  299. MedCDx
  300. MedGenome
  301. Medigen Biotechnology
  302. MediNcrease Health Plans
  303. MedStar Health
  304. Menarini Silicon Biosystems
  305. Merck
  306. Mercy BioAnalytics
  307. Metabolomic Technologies
  308. Metamark
  309. MGI Tech
  310. MiCareo
  311. Microgenomics
  312. Micromedic Technologies
  313. Milost Global
  314. Miltenyi Biotec
  315. Mindera
  316. Ministry of Health Singapore
  317. Minomic International
  318. MIODx
  319. miR Scientific
  320. MiRXES
  321. MolecularMatch
  322. MolecularMD
  323. MRM Proteomics
  324. multimmune
  325. Mumbai Angels
  326. Mursla
  327. Myriad Genetics
  328. Nan Fung Group
  329. Nanjing Kaiyuan Growth Capital Investments
  330. Nanostics
  331. NantHealth
  332. Natera
  333. National Cancer Institute
  334. National Institutes of Health
  335. National Taiwan University
  336. Naveris
  337. NEO New Oncology
  338. NeoGeneStar
  339. NeoGenomics
  340. Neon Therapeutics
  341. Netherlands Organization for Scientific Research
  342. NeuMoDx
  343. New Enterprise Associates
  344. New Jersey Economic Development Authority
  345. New Science Ventures
  346. NIRAMAI Health Analytix
  347. NM Genomix
  348. Nodexus
  349. N-of-One 
  350. Nonacus
  351. Norgen Biotek
  352. North Carolina Biotechnology Center
  353. Novartis
  354. Novigenix
  355. nRichDX
  356. Nucleix
  357. NueHealth
  358. NuGEN
  359. NuView Life Sciences
  360. NVIGEN
  361. OHSU Knight Cancer Institute
  362. oncgnostics
  363. Oncimmune
  364. OncoCyte
  365. Oncode Institute
  366. Oncode Scientific
  367. OncoDNA
  368. Oncolys BioPharma
  369. Oncore Pharma
  370. OncoSeek
  371. OPKO Health
  372. OrbiMed Advisors
  373. Örebro University Hospital
  374. ORI Healthcare Fund
  375. Owlstone Medical
  376. Oxford Gene Technology
  377. Pacific Edge
  378. PANAGENE
  379. Pangaea Oncology
  380. Pantai Premier Pathology
  381. Paragon Genomics
  382. Parampara Fund
  383. ParkwayHealth Laboratory
  384. PathGroup
  385. Perceptive Advisors
  386. PeriRx
  387. Personal Genome Diagnostics
  388. Pfizer
  389. Pillar Biosciences
  390. pluriSelect Life Science
  391. Polaris Partners
  392. Polymedco
  393. Polymer Char
  394. Positive Bioscience
  395. Precipio
  396. Precision for Medicine
  397. Predicine
  398. Prescient Metabiomics
  399. Prevail Partners
  400. Prime Value Capital Management
  401. Progenetics
  402. Prognos
  403. Prosperico Venture
  404. Protagen Diagnostics
  405. PROVIDENS
  406. Provista Diagnostics
  407. QIAGEN
  408. Qianjiang Capital
  409. Quantitative Cancer Diagnostix (QCDx)
  410. Quest Diagnostics
  411. Quidel
  412. RA Capital Management
  413. RainDance Technologies
  414. Rarecells Diagnostics
  415. RareCyte
  416. Regionalt Cancercentrum
  417. Reig Jofre Future Health
  418. Resolution Bioscience
  419. ResourcePath
  420. RGCC Group
  421. Roche
  422. Rongsheng Investment
  423. R-Pharm
  424. RT Ventures
  425. Sabartech
  426. SAGA Diagnostics
  427. Saha Fund
  428. Sambrinvest
  429. Sangel Capital
  430. SanoLiBio
  431. Sarah Cannon Research Institute
  432. Savicell Diagnostics
  433. Savran Technologies
  434. SB China Venture Capital
  435. ScreenCell
  436. Seer
  437. Sequoia Capital
  438. SeraCare Life Sciences
  439. Sevident
  440. Shanghai Fosun Long March Medical Science
  441. Shenzhen Innovation Investment Group
  442. Sienna Cancer Diagnostics
  443. Simfo
  444. Singapore Diagnostics
  445. Singlera Genomics
  446. Skåne University Hospital
  447. Société Régionale d'Investissement de Wallonie (SRIW)
  448. Sofina
  449. Sofinim
  450. Sofinnova Ventures
  451. SOPHiA GENETICS
  452. Speclipse
  453. StageZero Life Sciences
  454. STEMCELL Technologies
  455. Strand Life Sciences
  456. StrandSmart
  457. Streck
  458. Stroke Detection Plus
  459. Sungent BioVenture
  460. Sutter Hill Ventures
  461. Suzhou Kintor Pharmaceuticals
  462. Swift Biosciences
  463. Syncona Partners
  464. Sysmex Inostics
  465. T Rowe Price Associates
  466. Taiwan Government Industrial Development Bureau, Ministry of Economic     
  467. Takara Bio
  468. TAKE2
  469. Takeda
  470. Tarvand Sina Tajhiz
  471. TATAA Biocenter
  472. Tech Transfer UPV
  473. Telegraph Hill Partners
  474. Temasek
  475. Tempus
  476. Tencent
  477. The Heritage Group
  478. The University of Texas MD Anderson Cancer Center
  479. The W Fund
  480. Theranosis Life Sciences
  481. Thermo Fisher Scientific
  482. THG Ventures
  483. Thrive Earlier Detection
  484. Todos Medical
  485. Torna Kapital
  486. Torpedo Diagnostics
  487. Tranzend
  488. TSH Biopharm
  489. Tymora Analytical Operations
  490. UCF Medical Investment
  491. United States Department of Veterans Affairs
  492. Unitus Ventures
  493. Universal Diagnostics
  494. University Campus Bio-Medico of Rome
  495. University of Alabama at Birmingham 
  496. University of Minnesota
  497. University of Texas Health Science Center
  498. Varian Medical Systems
  499. Velox Biosystems
  500. Verily Life Sciences
  501. Viatar CTC Solutions
  502. Vienomics
  503. Vigilant Biosciences
  504. Vinsovier
  505. VisionGate
  506. VolitionRx
  507. Vortex Biosciences
  508. West Cancer Center
  509. Windham Venture Partners
  510. Wisemont Capital
  511. WntResearch
  512. Woodford Patient Capital Trust
  513. WRF Capital
  514. WS Investment
  515. WuXi NextCODE
  516. XboXLab
  517. X-ZELL
  518. Yahui Precision Medical Fund
  519. Yale School of Medicine
  520. Yi Fang Group
  521. Zehou Capital
  522. Zinexts Life Science
  523. Zodius
  524. Zogen Genética Molecular

Segmentation

The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:

  • Type of Tumor Marker
    • ctDNA
    • cfDNA
    • CTCs
    • Exosomes
    • Others 
  • Application
    • Diagnosis / Early Diagnosis
    • Patient Monitoring
    • Recurrence Monitoring 
  • Target Cancer Indication
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Bladder Cancer
    • Melanoma
    • Gastric Cancer
    • Pancreatic Cancer
    • Ovarian Cancer
    • Others
  • End Users
    • Hospitals
    • Research Institutes
    • Others
  • Key Geographical Regions 
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com